An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities.

ABSTRACT:

Background

Tumor-targeting IgE antibodies have elicited potent tumor-restricting effects by recruiting immune effector mechanisms. However, a dedicated platform for the generation, selection and evaluation of novel IgEs based on target antigen recognition and functional profiles has not been reported.

Methods

By establishing an IgE class antibody therapeutic design platform to allow selection of lead candidates, we generated a panel of IgEs recognising the human epidermal growth factor receptor 2 (HER2), overexpressed in 15-20% of breast cancers. From 1840 phage display-generated variable region sequences panned against HER2, we engineered 30 full length IgE antibodies. We selected three clones based on biophysical properties, reactivity to HER2 + cancer cells, epitope react

SUBMITTER: Palhares LCGF 

PROVIDER: S-EPMC11818027 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature